Healthcare Innovation

A landmark case could strip healthcare giants of a key legal defense, holding them accountable for allegedly deceiving seniors into for-profit Medicare plans.

A new federal grant positions Connecticut's HIE to solve a major privacy hurdle, testing tech that could transform care for SUD patients nationwide.

Landmark study results show a new drug-coated balloon significantly improves outcomes for Peripheral Artery Disease, heralding a major shift in treatment.

HealthEquity adds Sanford Health CEO Bill Gassen to its board, a strategic move to infuse provider-side expertise into the HSA giant's future.

Tenpoint Therapeutics launches YUVEZZI, a once-daily drop for presbyopia, entering a fierce market with a novel two-in-one formula for aging eyes.

Growth equity firm SEMCAP launches a new fund with Unilever Prestige visionary Vasiliki Petrou, targeting the booming wellness and longevity market.

Ephicacy appoints biometrics SVP Jamie Powers and India Head Tyagi Swaminathan in a strategic push to dominate advanced clinical trial analytics.

Pharma giant Sanofi inks a massive deal for Kali Therapeutics' KT501, a novel T-cell engager aiming to reset the immune system in autoimmune diseases.

A new book by a top physician-scientist challenges the idea that innovation comes from the private sector, arguing Medicaid is a lab for bold experiments.

Annovis Bio's new trial for buntanetap uses an AI-powered Apple Watch app to track symptoms, aiming for more precise data in the race for a cure.

The deal, part of a broader consolidation strategy by parent The Lockwood Group, aims to meet rising pharma demand for advanced data and patient services.

A new injectable dye entering Phase 3 trials promises to make lung cancer cells glow, helping surgeons remove tumors more completely and prevent recurrence.

JAMP Pharma Group introduces a generic version of a key prostate cancer drug, aiming to reduce healthcare costs and enhance patient support in Canada.

The spinal device firm will meet investors at the key small-cap conference, balancing a story of innovation against mixed financial results.

Bel Group's massive $200M investment in its South Dakota Babybel plant will double production, add 150 jobs, and capitalize on America's new snacking habits.

Thorne released impressive consumer data for its supplements. But what do these studies really mean for consumers in a crowded, unregulated market?

Newly published research brings scientific rigor to the controversial kratom plant, influencing policy from the FDA to statehouses across the nation.

The biotech plans to separate its R&D pipeline from its booming royalty assets, creating two public companies and winning applause from Wall Street.

With record 2025 revenue and a dominant hold on the gene therapy market, Cryoport's strategic investments pave a path toward profitability.

A 10-year, $25M program created 108 palliative care leaders. A new report reveals its impact on a field facing a critical workforce and access crisis.